$DCOYSep 29, 2026, 7:30 AM ETAI processed
DCOY preclinical PK supports once‑weekly intranasal dosing for DCOY‑CoV
AI Summary
Decoy Therapeutics (DCOY) reported preclinical pharmacokinetic data showing a single intranasal dose of its lead candidate DCOY‑CoV maintained drug levels above the company’s designed antiviral concentrations in nasal mucosa and lung tissue for up to seven days. The company says DCOY‑CoV is designed to protect against multiple endemic coronaviruses (including SARS‑CoV‑2) and plans to enter clinical trials in 2027; the data are preclinical and were presented at a peptide symposium.
Positives
- Single intranasal dose maintained tissue concentrations above designed antiviral levels in nasal mucosa and lung for up to 7 days (preclinical PK).
- DCOY‑CoV is designed to target multiple endemic human coronaviruses, not just one strain.
- Company expects to initiate clinical trials for DCOY‑CoV in 2027.
Negatives
- Results are preclinical only; no human safety or efficacy data yet.
- Data presented at a symposium (not a peer‑reviewed clinical readout).
- Company highlighted standard forward‑looking risks including financing and potential IND/clinical development hurdles.